Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro antimycobacterial activity of 5-chloropyrazinamide.

Literature DB >> 9527809

In vitro antimycobacterial activity of 5-chloropyrazinamide.

Abstract

5-Chloropyrazinamide and 5-chloropyrazinoic acid were evaluated for in vitro activity against Mycobacterium tuberculosis, Mycobacterium bovis, and several nontuberculous mycobacteria by a broth dilution method. 5-Chloropyrazinamide was more active than pyrazinamide against all organisms tested. It is likely that this agent has a different mechanism of action than pyrazinamide.

Entities: Chemical Species

Mesh：

Substances：

Year: 1998 PMID： 9527809 PMCID： PMC105437 DOI： 10.1128/AAC.42.2.462

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

Review 1. Present and new drug regimens in chemotherapy and chemoprophylaxis of tuberculosis.

Authors: J Grosset
Journal: Bull Int Union Tuberc Lung Dis Date: 1990 Jun-Sep

2. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.

Authors: H F Lecoeur; C Truffot-Pernot; J H Grosset
Journal: Am Rev Respir Dis Date: 1989-11

3. Pyrazinamide susceptibility and amidase activity of tubercle bacilli.

Authors: K Konno; F M Feldmann; W McDermott
Journal: Am Rev Respir Dis Date: 1967-03

4. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.

Authors: A Scorpio; P Lindholm-Levy; L Heifets; R Gilman; S Siddiqi; M Cynamon; Y Zhang
Journal: Antimicrob Agents Chemother Date: 1997-03 Impact factor: 5.191

5. Antimycobacterial activity of a series of pyrazinoic acid esters.

Authors: M H Cynamon; S P Klemens; T S Chou; R H Gimi; J T Welch
Journal: J Med Chem Date: 1992-04-03 Impact factor: 7.446

6. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?

Authors: L B Heifets; M A Flory; P J Lindholm-Levy
Journal: Antimicrob Agents Chemother Date: 1989-08 Impact factor: 5.191

7. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.

Authors: A Scorpio; Y Zhang
Journal: Nat Med Date: 1996-06 Impact factor: 53.440

8. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.

Authors: J B Bass; L S Farer; P C Hopewell; R O'Brien; R F Jacobs; F Ruben; D E Snider; G Thornton
Journal: Am J Respir Crit Care Med Date: 1994-05 Impact factor: 21.405

Review 9. Drug treatment of tuberculosis--1992.

Authors: P T Davidson; H Q Le
Journal: Drugs Date: 1992-05 Impact factor: 9.546

10. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.

Authors: R J Speirs; J T Welch; M H Cynamon
Journal: Antimicrob Agents Chemother Date: 1995-06 Impact factor: 5.191

23 in total

Review 1. Recent progress of isocyanide-based multicomponent reactions in Iran.

Authors: Ahmad Shaabani; Ali Maleki; Ali Hossein Rezayan; Afshin Sarvary
Journal: Mol Divers Date: 2010-07-29 Impact factor: 2.943

2. β-Lactam Combinations That Exhibit Synergy against Mycobacteroides abscessus Clinical Isolates.

Authors: Elizabeth Story-Roller; Christos Galanis; Gyanu Lamichhane
Journal: Antimicrob Agents Chemother Date: 2021-03-18 Impact factor: 5.191

3. Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.

Authors: Anthony D Baughn; Jiaoyu Deng; Catherine Vilchèze; Angelica Riestra; John T Welch; William R Jacobs; Oren Zimhony
Journal: Antimicrob Agents Chemother Date: 2010-09-27 Impact factor: 5.191

4. Select β-Lactam Combinations Exhibit Synergy against Mycobacterium abscessus In Vitro.

Authors: Elizabeth Story-Roller; Emily C Maggioncalda; Gyanu Lamichhane
Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191

5. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.

Authors: Helena I Boshoff; Valerie Mizrahi; Clifton E Barry
Journal: J Bacteriol Date: 2002-04 Impact factor: 3.490

6. Nonclassical transpeptidases of Mycobacterium tuberculosis alter cell size, morphology, the cytosolic matrix, protein localization, virulence, and resistance to β-lactams.

Authors: Maia K Schoonmaker; William R Bishai; Gyanu Lamichhane
Journal: J Bacteriol Date: 2014-01-24 Impact factor: 3.490

7. Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.

Authors: Amit Kaushik; Nayani Makkar; Pooja Pandey; Nicole Parrish; Urvashi Singh; Gyanu Lamichhane
Journal: Antimicrob Agents Chemother Date: 2015-08-10 Impact factor: 5.191

8. Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.

Authors: Silvana C Ngo; Oren Zimhony; Woo Jin Chung; Halimah Sayahi; William R Jacobs; John T Welch
Journal: Antimicrob Agents Chemother Date: 2007-05-07 Impact factor: 5.191

9. Characterization of Mycobacterium smegmatis expressing the Mycobacterium tuberculosis fatty acid synthase I (fas1) gene.

Authors: Oren Zimhony; Catherine Vilchèze; William R Jacobs
Journal: J Bacteriol Date: 2004-07 Impact factor: 3.490

10. Loss of a Functionally and Structurally Distinct ld-Transpeptidase, LdtMt5, Compromises Cell Wall Integrity in Mycobacterium tuberculosis.

Authors: Leighanne A Brammer Basta; Anita Ghosh; Ying Pan; Jean Jakoncic; Evan P Lloyd; Craig A Townsend; Gyanu Lamichhane; Mario A Bianchet
Journal: J Biol Chem Date: 2015-08-24 Impact factor: 5.157